First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments.
Clin Med Insights Oncol
; 16: 11795549221134735, 2022.
Article
in En
| MEDLINE
| ID: mdl-36387609
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Journal:
Clin Med Insights Oncol
Year:
2022
Document type:
Article